Gast ::
| Hauptseite > Publikationsdatenbank > OLHA (N-oleoylhistamine) modulates activity of mouse brain histaminergic neurons > print |
| Hauptseite > Publikationsdatenbank > OLHA (N-oleoylhistamine) modulates activity of mouse brain histaminergic neurons > print |
| 001 | 908294 | ||
| 005 | 20240625095110.0 | ||
| 024 | 7 | _ | |a 10.1016/j.neuropharm.2022.109167 |2 doi |
| 024 | 7 | _ | |a 0028-3908 |2 ISSN |
| 024 | 7 | _ | |a 1873-7064 |2 ISSN |
| 024 | 7 | _ | |a 2128/31381 |2 Handle |
| 024 | 7 | _ | |a 35750238 |2 pmid |
| 024 | 7 | _ | |a WOS:000826851500002 |2 WOS |
| 037 | _ | _ | |a FZJ-2022-02517 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Sergeeva, Olga A. |0 0000-0002-2713-1145 |b 0 |e Corresponding author |
| 245 | _ | _ | |a OLHA (N-oleoylhistamine) modulates activity of mouse brain histaminergic neurons |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2022 |b Elsevier Science |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1656334789_30066 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Histaminergic (HA) neurons are located in the tuberomamillary nucleus (TMN) of the posterior hypothalamus, from where they project throughout the whole brain to control wakefulness. We examined the effects of Nα-oleoylhistamine (OLHA), a non-enzymatic condensation product of oleic acid (OLA) and histamine, on activity of mouse HA neurons in brain slices. OLHA bidirectionally modulated the firing of HA neurons. At 10 nM OLHA inhibited or had no action, whereas at 1 μM it evoked excitatory and inhibitory responses. Inhibition was not seen in presence of the histamine receptor H3 (H3R) antagonist clobenpropit and in calcium-free medium. Pre-incubation with a histamine-reuptake blocker prevented the decrease in firing by OLHA. OLHA-evoked increase in firing (EC50 ∼44 nM) was insensitive to blockers of cannabinoid 1 and 2 receptors and of the capsaicin receptor, but was significantly impaired by the peroxisome proliferator-activated receptor-alpha (PPAR-alpha) antagonist MK886, which suppressed also the rise in intracellular calcium level caused by OLHA. The OLHA-evoked excitation was mimicked by synthetic PPAR-alpha agonists (gemfibrozil and GW7647) and was abolished by the PKA inhibitor H-89. The H3R affinity (Ki) for histamine, measured in HEK293 cells with stable expression of human H3R, was higher than for OLHA (Ki: 42 vs 310 nM, respectively). Expression of PPAR-alpha was not different between TMN regions of males and females, responses to OLHA did not differ. Molecular modelling of PPAR-alpha bound to either OLHA or OEA showed similar binding energies. These findings shed light on a novel biotransformation product of histamine which may play a role in health and disease. |
| 536 | _ | _ | |a 5241 - Molecular Information Processing in Cellular Systems (POF4-524) |0 G:(DE-HGF)POF4-5241 |c POF4-524 |f POF IV |x 0 |
| 536 | _ | _ | |a 5252 - Brain Dysfunction and Plasticity (POF4-525) |0 G:(DE-HGF)POF4-5252 |c POF4-525 |f POF IV |x 1 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Mazur, Karolina |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Reiner-Link, David |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Lutsenko, Kiril |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Haas, Helmut L. |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Alfonso-Prieto, Mercedes |0 P:(DE-Juel1)169976 |b 5 |u fzj |
| 700 | 1 | _ | |a Stark, Holger |0 P:(DE-HGF)0 |b 6 |
| 773 | _ | _ | |a 10.1016/j.neuropharm.2022.109167 |g Vol. 215, p. 109167 - |0 PERI:(DE-600)1500655-4 |p 109167 |t Neuropharmacology |v 215 |y 2022 |x 0028-3908 |
| 856 | 4 | _ | |y Published on 2022-06-21. Available in OpenAccess from 2023-06-21. |u https://juser.fz-juelich.de/record/908294/files/Sergeeva_Journal_Pre-Proof_2022.pdf |
| 856 | 4 | _ | |y Restricted |u https://juser.fz-juelich.de/record/908294/files/Sergeeva_Neuropharm_2022_SI.pdf |
| 909 | C | O | |o oai:juser.fz-juelich.de:908294 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 5 |6 P:(DE-Juel1)169976 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-524 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Molecular and Cellular Information Processing |9 G:(DE-HGF)POF4-5241 |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5252 |x 1 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-30 |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0 |0 LIC:(DE-HGF)CCBYNCND4 |2 HGFVOC |
| 915 | _ | _ | |a Embargoed OpenAccess |0 StatID:(DE-HGF)0530 |2 StatID |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-30 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2022-11-24 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-24 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEUROPHARMACOLOGY : 2021 |d 2022-11-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-24 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-24 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b NEUROPHARMACOLOGY : 2021 |d 2022-11-24 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)IAS-5-20120330 |k IAS-5 |l Computational Biomedicine |x 0 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-9-20140121 |k INM-9 |l Computational Biomedicine |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)IAS-5-20120330 |
| 980 | _ | _ | |a I:(DE-Juel1)INM-9-20140121 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|